AGA is excited to bring to you a CME/MOC/CE program developed in collaboration between AGA, the Crohn’s & Colitis Foundation and Medscape, “JAK Inhibitors for Ulcerative Colitis: Conversations From the Clinic.” Complete the program and empower yourself with the knowledge and confidence to integrate Janus kinase (JAK) inhibitors into your practice effectively.
Program highlights
JAK inhibitors represent a significant advancement in the treatment of ulcerative colitis (UC). Their efficacy and safety have been demonstrated in various clinical trials, making them a viable option for many patients.
Featuring insights from esteemed expert Aline Charabaty, MD, AGAF, FACG (Assistant Professor of Medicine, Division of Gastroenterology and Hepatology, and Clinical Director of the IBD Center at Sibley Memorial Hospital, Johns Hopkins School of Medicine), this program will offer participants the opportunity to:
- Review efficacy and safety data: Gain a comprehensive understanding of the latest data on JAK inhibitors, specifically tailored for patients with UC.
- Discuss risks and benefits: Enhance your ability to have informed discussions with your patients about the potential risks and benefits of JAK inhibitors.
- Compare patient populations: Learn how to compare the risks and benefits of JAK inhibitors across different patient populations with UC.
- Initiate therapy confidently: Acquire the skills needed to initiate JAK inhibitor therapy in appropriate patients, ensuring optimal outcomes.
Enroll now
Don’t miss this opportunity to elevate your practice. Enroll in the “JAK Inhibitors for Ulcerative Colitis: Conversations From the Clinic” program today and take a significant step towards mastering the use of JAK inhibitors in UC treatment.
